Long-chain acyl-CoA synthetase (ACSL) serves as a central regulatory node in cellular lipid metabolism, responsible for activating free long-chain fatty acids into acyl-CoAs, thereby channeling these fatty acids into downstream pathways such as oxidative energy production or complex lipid synthesis. The mammalian ACSL family comprises five isoforms-ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6-which exhibit significant differences in their tissue distribution, subcellular localization, and substrate preferences[1].
Specifically, ACSL3 inhibits lipid peroxidation by enriching monounsaturated fatty acids, thereby protecting tumor cells from damage. ACSL4 is predominantly enriched in adrenal and brain tissues; it specifically favors the activation of 20-carbon polyunsaturated fatty acids (PUFAs), acts as a core executor driving ferroptosis, and participates in the JAK-STAT1-IRF1 signaling axis. In various malignancies-such as hepatocellular carcinoma and breast cancer-ACSL4 exerts pro-tumorigenic effects and is associated with poor prognosis. Conversely, ACSL5 is primarily distributed in the intestine, localizes to mitochondria, and prefers 16-18 carbon fatty acids; it suppresses the Wnt signaling pathway by mediating the palmitoylation of the Wnt2B protein, typically functioning as a tumor suppressor gene and exerting protective effects in pancreatic cancer. However, in gastric cancer, ACSL5 is aberrantly overexpressed due to promoter hypomethylation, which paradoxically promotes the proliferation and metastasis of tumor cells[1][2][3].
The expression of the ACSL family is under strict regulation by signaling pathways-such as JAK-STAT and PPAR-as well as epigenetic mechanisms; functional abnormalities within this family are closely implicated in various malignancies-including hepatocellular carcinoma and breast cancer-as well as metabolic disorders. Inhibitors specifically targeting ACSL4 and ACSL5-such as troglitazone and tolcapone-hold potential for clinical application in precisely disrupting tumor metabolism or mitigating tissue damage[1][2][3].
Ferroptosis inducer-8 是一种对其他细胞死亡机制具有高选择性的铁死亡 (ferroptosis) 诱导剂,它通过影响 ACSL4、GPX4 和 FTH1 诱导铁死亡,破坏细胞内铁稳态和 GSH/GPX4 抗氧化防御系统,最终导致脂质过氧化积累,同时也能诱导 ROS 产生,并可抑制肿瘤生长,因此可用于三阴性乳腺癌 (TNBC) 的研究。
Ferroptosis inducer-9 是一种铁死亡 (ferroptosis) 诱导剂和秋水仙碱结合位点微管蛋白 (tubulin) 聚合抑制剂,以 IC50 为 14 nM 抑制 MCF-7 细胞生长并抑制 [3H]colchicine 结合,可降低 GPX4 和 FTH 的表达、提高 COX2 和 ACSL4、降低 GSH、NADP+ 和 NADPH 水平、提高 LPO、MDA 和 Fe(II) 水平并降低 SOD 浓度,在 HCT116 CRC 异种移植瘤模型中表现出显著的抗肿瘤功效,可用于研究三阴性乳腺癌 (TNBC) 和结直肠癌 (CRC)。
Ferroptosis/apoptosis inducer-5 是一种具有口服活性的铁死亡 (Ferroptosis) 和凋亡 (Apoptosis) 诱导剂,可下调 GPX4 并上调 ACSL4,促进 ROS 生成、Caspase 级联激活、线粒体功能障碍 (Mitochondrial dysfunction) 以及改变 Bcl-2/Bax 平衡,在胰腺癌异种移植小鼠模型中可显著抑制肿瘤生长,可用于胰腺癌的研究。
Fluorofenidone (Standard) 是 Fluorofenidone (AKF-PD) (MS-E54956) 的分析标准品,可用于研究及分析应用;Fluorofenidone 是一种具有口服活性的化合物,具有抗纤维化、抗氧化和抗炎的药理作用,可下调 ACSL4 表达、上调 GPX4 表达并抑制 NF-κB 信号通路以减轻炎症和纤维化,通过抑制小鼠肝脏的 Erk/-Egr-1 信号通路和 Tgfβ1/Smad 通路改善胆汁淤积和纤维化,在小鼠中对慢性肺损伤表现出保护作用,并可用于慢性阻塞性肺疾病 (COPD)、肺间质纤维化 (PIF) 和非小细胞肺癌 (NSCLC) 的研究。
Lepadin E 是一种具有显著细胞毒性的铁死亡 (ferroptosis) 诱导剂,通过经典 p53-SLC7A11-GPX4 途径诱导铁死亡,其机制为促进 p53 表达、降低 SLC7A11 和 GPX4 水平,从而导致 ROS 和脂质过氧化物产生增加并上调 ACSL4 表达,最终引起细胞死亡,具有显著抗肿瘤功效。
Lepadin H 是一种铁死亡 (ferroptosis) 诱导剂和细胞凋亡 (apoptosis) 诱导剂,对癌细胞具有体外细胞毒性和体内抗肿瘤功效,可通过降低 GPX4 和 SLC7A11 水平、提高肿瘤蛋白 p53 (p53) 和 ACSL4 表达、促进脂质氢过氧化物生成、升高活性氧 (ROS) 水平、降低细胞内谷胱甘肽 (GSH) 水平,诱导脂质过氧化及 G2/M 期细胞周期阻滞,并抑制癌细胞的克隆形成和迁移,可用于黑色素瘤的研究。
PROTAC FSP1 degrader 1 是一种靶向 FSP1 的高效且选择性 PROTAC 降解剂,可显著诱导细胞内脂质过氧化物积累,与 GPX4 抑制剂协同诱导铁死亡 (ferroptosis),诱导活性氧 (ROS) 产生,上调铁死亡相关蛋白的 mRNA 表达 (GPX4, FTH1, ACSL4, TfR1, FSP1),并可用于三阴性乳腺癌的研究 (粉色: FSP1 配体 (MS-I52917);蓝色: Cereblon 配体 (MS-Q68284);黑色: 连接子)。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号